nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.04.2014 | Original Article

FDG PET/CT in Crohn’s disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity

verfasst von: Babak Saboury, Ali Salavati, Alex Brothers, Sandip Basu, Thomas C. Kwee, Marnix G. E. H. Lam, Roland Hustinx, Edouard Louis, Drew A. Torigian, Abass Alavi

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to determine the feasibility and potential clinical utility of assessment of Crohn’s disease (CD) activity by ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT employing a new quantitative approach.

Methods

A total of 22 subjects (mean age 37) with CD who had undergone FDG PET/CT followed by ileocolonoscopy within 1 week were included in this analysis. The CD endoscopy index of severity (CDEIS) for various bowel segments was calculated. The CD activity index (CDAI) was evaluated, and fecal calprotectin was measured. On PET, regions with increased FDG uptake in large bowel were segmented with an adaptive contrast-oriented thresholding algorithm, and metabolically active volume (MAV), uncorrected mean standardized uptake value (SUV_mean), partial volume-corrected SUV_mean (PVC-SUV_mean), SUV_max, uncorrected total lesion glycolysis (TLG = MAV × SUV_mean), and PVC total lesion glycolysis (PVC-TLG = MAV × PVC-SUV_mean) were measured. Global CD activity score (GCDAS) was calculated as the sum of PVC-TLG over all clinically significant FDG-avid regions in each subject. Correlations between regional PET quantification measures (SUVs, TLGs) and CDEIS were calculated. Correlations between the global PET quantification measure (GCDAS, global SUVs) with CDAI, fecal calprotectin, CDEIS, and CRP level were also calculated.

Results

SUV_max, PVC-SUV_mean, and PVC-TLG significantly correlated with segment CDEIS subscores (r = 0.50, r = 0.69, and r = 0.31, respectively; p < 0.05). GCDAS significantly correlated with CDAI and fecal calprotectin (r = 0.64 and r = 0.51, respectively; p < 0.05).

Conclusion

By employing this new quantitative approach, we were able to calculate indices of regional and global CD activity, which correlated well with both clinical and pathological disease activity surrogate markers. This approach may be of clinical importance in measuring both global disease activity and treatment response in patients with CD.

Meuwis MA, Fillet M, Chapelle JP, Malaise M, Louis E, Merville MP. New biomarkers of Crohn’s disease: serum biomarkers and development of diagnostic tools. Expert Rev Mol Diagn 2008;8(3):327–37. doi:10.1586/14737159.8.3.327.PubMedCrossRef

Louis E, Belaiche J, Reenaers C. Anti-tumor necrosis factor nonresponders in Crohn’s disease: therapeutic strategies. Dig Dis 2009;27(3):351–7. doi:10.1159/000228573.PubMedCrossRef

Masselli G, Gualdi G. MR imaging of the small bowel. Radiology 2012;264(2):333–48. doi:10.1148/radiol.12111658.PubMedCrossRef

Maglinte DD, Sandrasegaran K, Lappas JC, Chiorean M. CT enteroclysis. Radiology 2007;245(3):661–71. doi:10.1148/radiol.2453060798.PubMedCrossRef

Chiorean MV, Sandrasegaran K, Saxena R, Maglinte DD, Nakeeb A, Johnson CS. Correlation of CT enteroclysis with surgical pathology in Crohn’s disease. Am J Gastroenterol 2007;102(11):2541–50. doi:10.1111/j.1572-0241.2007.01537.x.PubMedCrossRef

Bettenworth D, Reuter S, Hermann S, Weckesser M, Kerstiens L, Stratis A, et al. Translational 18F-FDG PET/CT imaging to monitor lesion activity in intestinal inflammation. J Nucl Med 2013;54(5):748–55. doi:10.2967/jnumed.112.112623.PubMedCrossRef

Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med 2010;51(12):1937–49. doi:10.2967/jnumed.110.076232.PubMed

Groshar D, Bernstine H, Stern D, Sosna J, Eligalashvili M, Gurbuz EG, et al. PET/CT enterography in Crohn disease: correlation of disease activity on CT enterography with 18F-FDG uptake. J Nucl Med 2010;51(7):1009–14. doi:10.2967/jnumed.109.073130.PubMedCrossRef

Jacene HA, Ginsburg P, Kwon J, Nguyen GC, Montgomery EA, Bayless TM, et al. Prediction of the need for surgical intervention in obstructive Crohn’s disease by 18F-FDG PET/CT. J Nucl Med 2009;50(11):1751–9. doi:10.2967/jnumed.109.065466.PubMedCrossRef

10.

Louis E, Ancion G, Colard A, Spote V, Belaiche J, Hustinx R. Noninvasive assessment of Crohn’s disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med 2007;48(7):1053–9. doi:10.2967/jnumed.107.040436.PubMedCrossRef

11.

Vucelic B. Inflammatory bowel diseases: controversies in the use of diagnostic procedures. Dig Dis 2009;27(3):269–77. doi:10.1159/000228560.PubMedCrossRef

12.

Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med 2009;39(2):124–45. doi:10.1053/j.semnuclmed.2008.10.006.PubMedCrossRef

13.

Shyn PB. 18F-FDG positron emission tomography: potential utility in the assessment of Crohn’s disease. Abdom Imaging 2012;37(3):377–86. doi:10.1007/s00261-011-9793-y.PubMedCrossRef

14.

Treglia G, Quartuccio N, Sadeghi R, Farchione A, Caldarella C, Bertagna F, et al. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with chronic inflammatory bowel disease: a systematic review and a meta-analysis. J Crohns Colitis 2013;7(5):345–54. doi:10.1016/j.crohns.2012.08.005.PubMedCrossRef

15.

Neurath MF, Vehling D, Schunk K, Holtmann M, Brockmann H, Helisch A, et al. Noninvasive assessment of Crohn’s disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 2002;97(8):1978–85. doi:10.1111/j.1572-0241.2002.05836.x.PubMedCrossRef

16.

Kresnik E, Mikosch P, Gallowitsch HJ, Heinisch M, Lind P. F-18 fluorodeoxyglucose positron emission tomography in the diagnosis of inflammatory bowel disease. Clin Nucl Med 2001;26(10):867.PubMedCrossRef

17.

Pio BS, Byrne FR, Aranda R, Boulay G, Spicher K, Song MH, et al. Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-D-glucose-labeled white blood cells. Mol Imaging Biol 2003;5(4):271–7.PubMedCrossRef

18.

Lemberg DA, Issenman RM, Cawdron R, Green T, Mernagh J, Skehan SJ, et al. Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis 2005;11(8):733–8.PubMedCrossRef

19.

Löffler M, Weckesser M, Franzius C, Schober O, Zimmer KP. High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci 2006;1072:379–85. doi:10.1196/annals.1326.014.PubMedCrossRef

20.

Meisner RS, Spier BJ, Einarsson S, Roberson EN, Perlman SB, Bianco JA, et al. Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis 2007;13(8):993–1000. doi:10.1002/ibd.20134.PubMedCrossRef

21.

Rubin DT, Surma BL, Gavzy SJ, Schnell KM, Bunnag AP, Huo D, et al. Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission. Inflamm Bowel Dis 2009;15(5):750–5. doi:10.1002/ibd.20819.PubMedCrossRef

22.

Spier BJ, Perlman SB, Jaskowiak CJ, Reichelderfer M. PET/CT in the evaluation of inflammatory bowel disease: studies in patients before and after treatment. Mol Imaging Biol 2010;12(1):85–8. doi:10.1007/s11307-009-0232-1.PubMedCrossRef

23.

Ahmadi A, Li Q, Muller K, Collins D, Valentine JF, Drane W, et al. Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography enterography in active Crohn’s disease. Inflamm Bowel Dis 2010;16(6):974–81. doi:10.1002/ibd.21153.PubMedCrossRef

24.

Halpenny DF, Burke JP, Lawlor GO, O’Connell M. Role of PET and combination PET/CT in the evaluation of patients with inflammatory bowel disease. Inflamm Bowel Dis 2009;15(6):951–8. doi:10.1002/ibd.20817.PubMedCrossRef

25.

Däbritz J, Jasper N, Loeffler M, Weckesser M, Foell D. Noninvasive assessment of pediatric inflammatory bowel disease with (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography. Eur J Gastroenterol Hepatol 2011;23(1):81–9. doi:10.1097/MEG.0b013e3283410222.PubMedCrossRef

26.

Lapp RT, Spier BJ, Perlman SB, Jaskowiak CJ, Reichelderfer M. Clinical utility of positron emission tomography/computed tomography in inflammatory bowel disease. Mol Imaging Biol 2011;13(3):573–6. doi:10.1007/s11307-010-0367-0.PubMedCrossRef

27.

Spier BJ, Perlman SB, Reichelderfer M. FDG-PET in inflammatory bowel disease. Q J Nucl Med Mol Imaging 2009;53(1):64–71.PubMed

28.

Horsthuis K, Bipat S, Bennink RJ, Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology 2008;247(1):64–79. doi:10.1148/radiol.2471070611.PubMedCrossRef

29.

Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008;57(11):1518–23. doi:10.1136/gut.2007.146357.PubMedCrossRef

30.

Alavi A, Newberg AB, Souder E, Berlin JA. Quantitative analysis of PET and MRI data in normal aging and Alzheimer’s disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med 1993;34(10):1681–7.PubMed

31.

Torigian DA, Lopez RF, Alapati S, Bodapati G, Hofheinz F, van den Hoff J, et al. Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT. Hell J Nucl Med 2011;14(1):8–14.PubMed

32.

Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med 2012;53(12):1829–35. doi:10.2967/jnumed.112.106500.PubMedCrossRef

33.

Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med 2012;53(10):1506–13. doi:10.2967/jnumed.111.101402.PubMedCrossRef

34.

Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun 2008;29(6):521–6. doi:10.1097/MNM.0b013e3282f813a4.PubMedCrossRef

35.

Hernandez-Martinez A, Marin-Oyaga VA, Salavati A, Saboury B, Codreanu I, Lam MG, et al. Quantitative assessment of global hepatic glycolysis in patients with cirrhosis and normal controls using 18F-FDG-PET/CT: a pilot study. Ann Nucl Med 2013. doi:10.1007/s12149-013-0780-y.

36.

Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2012;39(1):27–38. doi:10.1007/s00259-011-1934-6.PubMedCrossRef

37.

Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007;48(9):1449–58. doi:10.2967/jnumed.107.042333.PubMedCrossRef

38.

Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med 2012;53(5):709–15. doi:10.2967/jnumed.111.099531.PubMedCrossRef

39.

Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30(7):983–9.PubMedCentralPubMedCrossRef

40.

Best WR, Becktel JM, Singleton JW, Kern Jr F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976;70(3):439–44.PubMed

41.

Hofheinz F, Langner J, Petr J, Beuthien-Baumann B, Oehme L, Steinbach J, et al. A method for model-free partial volume correction in oncological PET. EJNMMI Res 2012;2(1):16. doi:10.1186/2191-219X-2-16.PubMedCentralPubMedCrossRef

42.

Hofheinz F, Dittrich S, Pötzsch C, Hoff J. Effects of cold sphere walls in PET phantom measurements on the volume reproducing threshold. Phys Med Biol 2010;55(4):1099–113. doi:10.1088/0031-9155/55/4/013.PubMedCrossRef

43.

Schaefer A, Kim YJ, Kremp S, Mai S, Fleckenstein J, Bohnenberger H, et al. PET-based delineation of tumour volumes in lung cancer: comparison with pathological findings. Eur J Nucl Med Mol Imaging 2013;40(8):1233–44. doi:10.1007/s00259-013-2407-x.PubMedCrossRef

44.

Schaefer A, Kremp S, Hellwig D, Rübe C, Kirsch CM, Nestle U. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging 2008;35(11):1989–99. doi:10.1007/s00259-008-0875-1.PubMedCrossRef

45.

Musiek ES, Saboury B, Mishra S, Chen Y, Reddin JS, Newberg AB, et al. Feasibility of estimation of brain volume and 2-deoxy-2-(18)F-fluoro-D-glucose metabolism using a novel automated image analysis method: application in Alzheimer’s disease. Hell J Nucl Med 2012;15(3):190–6. doi:10.1967/s002449910052.PubMed

46.

Abdulla S, Salavati A, Saboury B, Basu S, Torigian DA, Alavi A. Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study. Eur J Nucl Med Mol Imaging 2013. doi:10.1007/s00259-013-2579-4.PubMed

47.

Toriihara A, Yoshida K, Umehara I, Shibuya H. Normal variants of bowel FDG uptake in dual-time-point PET/CT imaging. Ann Nucl Med 2011;25(3):173–8. doi:10.1007/s12149-010-0439-x.PubMedCrossRef

48.

Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008;14(3):354–77.PubMedCentralPubMedCrossRef

49.

Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120(1):13–20.PubMedCrossRef

50.

Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn’s disease: monitoring disease activity. Aliment Pharmacol Ther 2003;17 Suppl 2:11–7.PubMedCrossRef

51.

Holtmann MH, Uenzen M, Helisch A, Dahmen A, Mudter J, Goetz M, et al. 18F-Fluorodeoxyglucose positron-emission tomography (PET) can be used to assess inflammation non-invasively in Crohn’s disease. Dig Dis Sci 2012;57(10):2658–68. doi:10.1007/s10620-012-2190-8.PubMedCrossRef

52.

Hindryckx P, Staelens S, Devisscher L, Deleye S, De Vos F, Delrue L, et al. Longitudinal quantification of inflammation in the murine dextran sodium sulfate-induced colitis model using μPET/CT. Inflamm Bowel Dis 2011;17(10):2058–64. doi:10.1002/ibd.21578.PubMedCrossRef

53.

Brewer S, McPherson M, Fujiwara D, Turovskaya O, Ziring D, Chen L, et al. Molecular imaging of murine intestinal inflammation with 2-deoxy-2-[18F]fluoro-D-glucose and positron emission tomography. Gastroenterology 2008;135(3):744–55. doi:10.1053/j.gastro.2008.06.040.PubMedCentralPubMedCrossRef

54.

Wang H, Machtaler S, Bettinger T, Lutz AM, Luong R, Bussat P, et al. Molecular imaging of inflammation in inflammatory bowel disease with a clinically translatable dual-selectin-targeted US contrast agent: comparison with FDG PET/CT in a mouse model. Radiology 2013;267(3):818–29. doi:10.1148/radiol.13122509.PubMedCrossRef

55.

Basu S, Zaidi H, Houseni M, Bural G, Udupa J, Acton P, et al. Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states. Semin Nucl Med 2007;37(3):223–39.PubMedCrossRef

56.

Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48(6):932–45. doi:10.2967/jnumed.106.035774.PubMedCrossRef

57.

Dewaraja YK, Ljungberg M, Koral KF. Monte Carlo evaluation of object shape effects in iodine-131 SPET tumor activity quantification. Eur J Nucl Med 2001;28(7):900–6.PubMedCentralPubMedCrossRef

Titel: FDG PET/CT in Crohn’s disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity
verfasst von: Babak Saboury
Ali Salavati
Alex Brothers
Sandip Basu
Thomas C. Kwee
Marnix G. E. H. Lam
Roland Hustinx
Edouard Louis
Drew A. Torigian
Abass Alavi
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2625-2

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients

Molecular imaging of brown adipose tissue in health and disease

Diffusion and perfusion correlates of the 18F-MISO PET lesion in acute stroke: pilot study

Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone

The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE)

Comparative evaluation of CT-based and respiratory-gated PET/CT-based planning target volume (PTV) in the definition of radiation treatment planning in lung cancer: preliminary results